Principal Investigator
Justin Watts
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240780
Clinical Trial Summary
A phase II study of venetoclax (ABT-199) in combination with cladribine and low-dose cytarabine alternating with azacitidine plus venetoclax in newly diagnosed monocytic AML and active signaling mutated AML
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Leukemia
Contact Information
Phone Number
305-243-2647